partnering

News

UK biotech Dunad inks $1.3bn Novartis deal for its protein d...

In only its second year of operations, Cambridge, UK startup Dunad Therapeutics has already attracted a big pharma partner for its protein degradation platform.

News

AZ/Daiichi partner with Merck on first-line lung cancer tria...

The dominance of Merck & Co's Keytruda in the treatment of previously-untreated non-small cell lung cancer (NSCLC) means it will be hard to dislodge – so AstraZeneca and Daiichi Sankyo

News

Janssen J&J Johnson and Johnson pharmaceutical companies

J&J bulks up in bispecifics with $1.3bn Xencor alliance

Fresh from claiming its first bispecific antibody approval, Johnson & Johnson has delved deeper into the category with a deal to license a drug for B-cell cancers developed by Xencor.

News

Roche dives further into cancer cell therapy with Adaptimmun...

Roche has largely been a spectator on the side lines as other drugmakers have embraced cell therapies for cancer, but it has made a big play now, pledging $150 million upfront to an allianc

News

Lilly taps Lycia for protein degrader tech in $1.6bn deal

Eli Lilly has bolstered its position the fast-emerging area of protein degrader drugs, agreeing a $1.6 billion-plus deal with Lycia Therapeutics spanning up to five drug targets.

News